Early Access

10-KPeriod: FY2019

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2019

Filed February 7, 2020For Securities:ISRG

Summary

Intuitive Surgical, Inc. (ISRG) demonstrated strong growth in its 2019 fiscal year, with total revenue increasing by 20% to $4.5 billion, driven by a 23% increase in instrument and accessory revenue and a 19% increase in systems revenue. The company shipped 1,119 da Vinci Surgical Systems, a 21% increase year-over-year, and expanded its installed base to 5,582 systems. Procedures performed globally increased by 18% to approximately 1.23 million. The company continues to invest heavily in research and development, with a 33% increase in R&D expenses, focusing on expanding its product offerings and improving existing technologies. The introduction of new products like the Ion endoluminal system for diagnostic procedures and continued rollout of the da Vinci SP surgical system highlight the company's commitment to innovation. Despite a slight decrease in gross profit margin to 69.4% primarily due to increased amortization expenses from acquisitions, the company maintained robust profitability with operating income growing by 15% to $1.4 billion.

Financial Statements
Beta

Key Highlights

  • 1Total revenue grew 20% to $4.5 billion in 2019.
  • 2Global da Vinci procedures increased by 18% to 1.23 million in 2019.
  • 3Instrument and accessory revenue, a key recurring revenue stream, grew 23% to $2.4 billion.
  • 4System shipments increased by 21% to 1,119 units, expanding the installed base to 5,582 systems.
  • 5Research and Development expenses increased by 33%, reflecting continued investment in innovation.
  • 6The company began commercial sales of its new Ion endoluminal system for diagnostic procedures.
  • 7Operating income grew 15% to $1.4 billion, demonstrating strong profitability.

Frequently Asked Questions